Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Rating) dropped 23.5% during mid-day trading on Thursday . The stock traded as low as $2.13 and last traded at $2.13. Approximately 350 shares were traded during trading, a decline of 3% from the average daily volume of 361 shares. The stock had previously closed at $2.79.
Defence Therapeutics Trading Down 23.5 %
The company’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $2.84.
Defence Therapeutics Company Profile
Defence Therapeutics Inc, a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Read More
- Get a free copy of the StockNews.com research report on Defence Therapeutics (DTCFF)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
